IGC Pharma, Inc. (IGC)
NYSEAMERICAN: IGC · Real-Time Price · USD
0.263
+0.001 (0.42%)
Jun 26, 2026, 4:00 PM EDT - Market closed
IGC Pharma Employees
IGC Pharma had 70 employees as of March 31, 2025. The number of employees increased by 3 or 4.48% compared to the previous year.
Employees
70
Change (1Y)
3
Growth (1Y)
4.48%
Revenue / Employee
$15,800
Profits / Employee
-$92,086
Market Cap
26.32M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Vistagen Therapeutics | 59 |
| Evaxion | 46 |
| Kyntra Bio | 34 |
| Plus Therapeutics | 28 |
| NeuroSense Therapeutics | 17 |
| Quantum BioPharma | 17 |
| Serina Therapeutics | 16 |
| BriaCell Therapeutics | 16 |
IGC News
- 4 days ago - IGC Pharma announced beta version of Agentic Harmonization Assistant - TheFly
- 4 days ago - IGC Pharma's AHA Agentic AI Platform Reduces Alzheimer's Data Harmonization Time by 90% in Representative Workflow - Accesswire
- 16 days ago - IGC Pharma reaches 146-patient enrollment target for Phase 2 Calma trial - TheFly
- 16 days ago - IGC Pharma Reaches Previously Disclosed 146-Patient Enrollment Target in Phase 2 CALMA Trial, Advancing Toward Topline Analysis - Accesswire
- 18 days ago - Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.50, Citing Clinical Progress and 2026 Catalysts - Accesswire
- 25 days ago - IGC Pharma adds Mount Sinai clinical site as CALMA trial advances - TheFly
- 25 days ago - IGC Pharma Adds Mount Sinai Clinical Site as CALMA Trial Advances Toward Completion and Topline Analysis - Accesswire
- 5 weeks ago - IGC Pharma Reports First Quarter 2026 Financial Results with CALMA Phase 2 in the final stage, with 80% Enrollment - Accesswire